title: Targeted purification development enabled by computational biophysical modeling.
abstract: Chromatographic and non-chromatographic purification of biopharmaceuticals depend on the interactions between protein molecules and a solid-liquid interface. These interactions are dominated by the protein-surface properties, which are a function of protein sequence, structure, and dynamics. In addition, protein-surface properties are critical for in vivo recognition and activation, thus, purification strategies should strive to preserve structural integrity and retain desired pharmacological efficacy. Other factors such as surface diffusion, pore diffusion, and film mass transfer can impact chromatographic separation and resin design. The key factors that impact non-chromatographic separations (e.g., solubility, ligand affinity, charges and hydrophobic clusters, and molecular dynamics) are readily amenable to computational modeling and can enhance the understanding of protein chromatographic. Previously published studies have used computational methods such as quantitative structure-activity relationship (QSAR) or quantitative structure-property relationship (QSPR) to identify and rank order affinity ligands based on their potential to effectively bind and separate a desired biopharmaceutical from host cell protein (HCP) and other impurities. The challenge in the application of such an approach is to discern key yet subtle differences in ligands and proteins that influence biologics purification. Using a relatively small molecular weight protein (insulin), this research overcame limitations of previous modeling efforts by utilizing atomic level detail for the modeling of protein-ligand interactions, effectively leveraging and extending previous research on drug target discovery. These principles were applied to the purification of different commercially available insulin variants. The ability of these computational models to correlate directionally with empirical observation is demonstrated for several insulin systems over a range of purification challenges including resolution of subtle product variants (amino acid misincorporations). Broader application of this methodology in bioprocess development may enhance and speed the development of a robust purification platform.
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc, Whitehouse Station, NJ, 08889.
authors.forename: Francis K
authors.initials: FK
authors.lastname: Insaidoo
authors.forename: Michael A
authors.initials: MA
authors.lastname: Rauscher
authors.forename: Shepard J
authors.initials: SJ
authors.lastname: Smithline
authors.forename: Niels C
authors.initials: NC
authors.lastname: Kaarsholm
authors.forename: Bradley P
authors.initials: BP
authors.lastname: Feuston
authors.forename: Allison D
authors.initials: AD
authors.lastname: Ortigosa
authors.forename: Thomas O
authors.initials: TO
authors.lastname: Linden
authors.forename: David J
authors.initials: DJ
authors.lastname: Roush
mesh_terms: D000595:Amino Acid Sequence; D001709:Biotechnology / Q000379:methods*; D005591:Chemical Fractionation; D002853:Chromatography, Liquid / Q000379:methods*; D006863:Hydrogen-Ion Concentration; D062105:Molecular Docking Simulation; D056004:Molecular Dynamics Simulation; D008969:Molecular Sequence Data; D011485:Protein Binding; D011506:Proteins / Q000032:analysis / Q000737:chemistry / Q000302:isolation & purification*
chemical_list: D011506:Proteins
keywords: and interaction energy; bioprocess development; bioseparation; column chromatography; ligand docking; molecular dynamics simulation